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Abstract
Objective
To describe the histopathologic features of a case of facial-onset sensory and motor neuron-
opathy (FOSMN).
Methods
We describe a postmortem examination performed on a 54-year-old man with FOSMN as-
sociated with personality change.
Results
Postmortem examination revealed TAR DNA-binding protein (TDP) 43 proteinopathy with
widespread distribution. TDP43 pathology was seen in the neurons and glial cells and was most
pronounced in the subthalamic nucleus followed by the spinal cord, including dorsal root
ganglia, brainstem, and other deep cerebral nuclei. In the medial temporal lobe, neocortex and
subcortical hemispheric white matter TDP43 pathologic inclusions were very rare. In contrast
to TDP43 pathologies associated with typical amyotrophic lateral sclerosis (ALS) or fronto-
temporal dementia (FTD)–TDP, in this case, there were more frequent TDP43-positive
oligodendroglial, coiled body–like cytoplasmic inclusions than neuronal inclusions. Neuronal
cytoplasmic TDP43 inclusions with globular and skein-like morphology were seen in both
anterior horn cells and dorsal root ganglia. No β-amyloid, α-synuclein, or signiﬁcant hyper-
phosphorylated tau pathology was seen.
Conclusion
This case provides further evidence that FOSMN is a neurodegenerative disease characterized
by TDP43 pathology. Despite minimal cortical TDP43 pathology, the clinical features of the
behavioral variant of FTD in this patient suggest that FOSMN may fall within or overlap with
the FTD-ALS spectrum.
From the MRC Centre for Neuromuscular Diseases (A.M.R., M.M.R.), Department of Neurodegenerative Disease (Z.J.), Queen Square Brain Bank (Z.J., G.H.), and Dementia Research
Centre (M.N.R.), UCL Institute of Neurology; National Hospital for Neurology and Neurosurgery (A.M.R., M.M.R., M.N.R.); and Division of Neuropathology (Z.J.), National Hospital for
Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, Queen Square, UK.
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
The Article Processing Charge was funded by Wellcome Trust.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. e1
 Published Ahead of Print on January 30, 2019 as 10.1212/WNL.0000000000007008
Facial-onset sensory and motor neuronopathy (FOSMN) is
a rare clinical syndrome characterized by asymmetric facial
numbness or paresthesia, bulbar palsy, and facial weakness,
which may progress to the upper limbs.1 The FOSMN syn-
drome was ﬁrst described in 2006, and since then, >40 cases
have been described.2,3 Onset is typically in the ﬁfth to sev-
enth decade (but has been reported in patients as young as 7
years of age4), and the rate of progression can vary from
months to decades.
The pathogenesis of FOSMN remains controversial. Initial
reports described the presence of anti-ganglioside antibodies
and response to immunotherapy,5 whereas others have de-
scribed a progressive and terminal decline, resistant to im-
munotherapy and suggestive of bulbar-onset amyotrophic
lateral sclerosis (ALS).3,6–8 Two of 3 postmortem studies of
patients with FOSMN have revealed the presence of TAR
DNA-binding protein (TDP) 43 inclusions in the brainstem
nuclei and cervical motor neurons.3,7,8 In this article, we de-
scribe a patient with FOSMN and behavioral change in whom
postmortem examination revealed frequent pathologic
TDP43 inclusions in the deep cerebral nuclei, brainstem, and
spinal cord and rarely in the medial temporal lobe, frontal
cortex, and dorsal root ganglia (DRG).
Methods
Formalin-ﬁxed, paraﬃn-embedded brain and spinal cord tis-
sue was available from selected regions (table 1). The paraﬃn
sections were cut at 5 μm,mounted on glass slides, and stained
with routine hematoxylin and eosin. Representative 5-μm
sections were immunostained for TDP43, β-amyloid, α-syn-
uclein, hyperphosphorylated tau, p62, and CD68 with the
following antibodies: TDP43 (2E2-D3, 1:3,000, Abcam,
Cambridge, UK), β-amyloid (6F3D, 1:50, DAKO, Glostrup,
Denmark), α-synuclein (KM51, 1:50, Leica/Novocastra,
Buﬀalo Grove, IL), AT8, (MN1020, 1:100, Invitrogen,
Carlsbad, CA), p62 (3/P62LCK Ligand, 1:100, BD Trans-
duction, East Rutherford, NJ), and CD68 (PG-M1, 1:100,
DAKO), respectively. Immunostaining was performed on
either a BondMax autostainer (Leica Microsystems, Wetzlar,
Germany) or a Roche (Basel, Switzerland) Ventana Discov-
ery automated staining platform following the manufacturer’s
guidelines, using biotinylated secondary antibodies and
a horseradish peroxidase–conjugated streptavidin complex
and diaminobenzidine as a chromogen. All immunostainings
were carried with appropriate controls. Gliosis, microglial
activity, and the density of TDP43 pathologic inclusions were
scored semiquantitatively.
Data availability statement
All data relevant to this study are contained within the
manuscript.
Results
A 54-year-old right-handed man presented with symptoms of
facial numbness, dysarthria, and dysphagia and inappropriate
behavior. Nine years previously, after a dental extraction, he
developed numbness of the left upper lip that over 5 years
spread to involve his tongue and left cheek and was associated
with dysphagia and nasal regurgitation. A collateral history
obtained from his wife reported that since the onset of the
dysphagia, the patient’s behavior had changed and he had
diﬃculty maintaining his train of thought. There was no
family history of neurodegenerative disease.
A Mini-Mental State Examination was normal; however, he
was noted to have an inappropriate jocular manner. Clinical
examination revealed a cachectic man. There was diminished
light touch sensation in all territories of the trigeminal nerve
and diminished pinprick sensation in the left mandibular
territory. The corneal reﬂexes were absent. There was bilateral
facial myokymia. The gag reﬂex was absent, and there was
weakness of neck ﬂexion, along with wasting and fasciculation
of the tongue. In the upper limbs, there was wasting and
weakness of the deltoids. There was no wasting, weakness, or
sensory disturbance of the lower limbs. The knee and ankle
reﬂexes were preserved, and the plantar responses were absent.
Nerve conduction studies performed 5 years after the onset of
his symptoms revealed normal sensory and motor action
potentials and conduction velocities in the upper and lower
limbs (table 2). EMG demonstrated large individual motor
units ﬁring at high rates in a grossly reduced interference
pattern, indicative of chronic denervation, in the sternoclei-
domastoid and orbicularis oculi. There was no evidence of
acute denervation. Blink reﬂexes were absent bilaterally.
MRI scans of the brain and spine were normal. Fluorodeox-
yglucose PET CT scan revealed an enlarged jugular lymph
node that was subsequently biopsied and showed nonspeciﬁc
reactive lymphoid hyperplasia. Duodenal biopsies were neg-
ative forWhipple disease. A lip biopsy was unremarkable. CSF
examination was normal, including oligoclonal bands and
Whipple PCR. Genetic testing for Kennedy disease,
dentatorubral-pallidoluysian atrophy, and spinocerebellar
ataxia types 1, 2, 3, 6, and 7 was negative. Routine blood tests
were all normal.
Glossary
ALS = amyotrophic lateral sclerosis; DRG = dorsal root ganglia; FOSMN = facial-onset sensory and motor neuronopathy;
GCI = oligodendroglial coiled body–like cytoplasmic inclusion; NCI = neuronal cytoplasmic inclusion; TDP = TAR DNA-
binding protein.
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Table 1 Available and analyzed brain and spinal cord regions
Region
Neuronal
loss/gliosis
TDP43 and
p62 NII
TDP43 and
p62 NCI
TDP43 and
p62 GCI
TDP43 and p62 DN
long, thick
TDP43 and p62 DN
short, thin
Dorsal root ganglion, level NOS + − + − − −
Anterior horn cells (lumbar) +/− − + ++ − ++
Substantia gelatinosa
(thoracolumbar)
+/− − − + − −
White matter, spinal cord NA NA NA + − −
12th nucleus +/− − − ++ − +
10th nucleus +/− − − + − −
Medulla tegmentum
(including fifth nucleus)
+/− − + ++ − ++
Inferior olivary nucleus − − + + − +
Pyramidal tract NA NA NA − − −
Substantia nigra + − + ++ − ++
Red nucleus − − − ++ − +
Midbrain cerebral peduncle − NA NA + − +
Third nucleus − − − + − +
Midbrain tegmentum − NA NA ++ − +
Anterior hippocampus − − − CA1&4 + − −
Dentate gyrus − − − − − −
Parahippocampal gyrus − − − − − −
Amygdala − − − + − +
Cingulate gyrus − − + − − −
Putamen − − + ++ − +
Globus pallidus − − + ++ − +
Pencil fibres NA NA NA ++ − +
Thalamus − − + ++ − −
Subthalamic nucleus +++ − − +++ − +
Insular cortex − − − − − −
Neocortex, NOS − − + + +
Subcortical white matter, NOS − NA NA + − +
Occipital lobe − − − − − −
Motor cortex − − + − − +
Betz cells − − − NA NA NA
Purkinje cells + − − − − −
Granule cells − − − − − −
Dentate nucleus − − + − − −
Cerebellar white matter − NA NA ++ − +
Abbreviations: DN = dystrophic neurites; GCI = glial cytoplasmic inclusions; NA = not applicable; NCI = neuronal cytoplasmic inclusions; NII = neuronal
intranuclear inclusions; NOS = not otherwise specified; TDP43 = TAR DNA-binding protein 43; − = absent inclusions or no neuronal loss or no gliosis; +/− = no
overt loss; +, ++, +++ = rare, moderate, frequent inclusions, respectively.
Neuronal loss, gliosis, and TDP43-positive pathologic inclusions are scored semiquantitatively.
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Formal neuropsychometry demonstrated a verbal IQ of 115
and performance IQ of 114, with average subtest scores ex-
cept for arithmetic and picture completion, which were su-
perior. Recognition memory tests were almost ﬂawless
(words 48 of 50, faces 50 of 50). Although he performed
adequately on tests sensitive to frontal lobe dysfunction, he
was noted to be inappropriately jocular during testing.
The patient was diagnosed with a progressive brainstem
syndrome. In hindsight, the clinical syndrome is FOSMN, but
this diagnosis had not been described at the time the patient
presented. Because an inﬂammatory brainstem disorder
remained a possibility, the patient was treated with a 3-month
course of oral steroids, but his condition continued to de-
teriorate, and he was readmitted to hospital with an aspiration
pneumonia. A percutaneous gastrostomy tube was inserted,
but against medical advice, he continued to eat and drink,
leading to a ﬁnal episode of aspiration pneumonia, of which he
died, 9 years after the onset of his symptoms.
Postmortem examination
Pathologic TDP43-positive inclusions were seen in the form
of neuronal cytoplasmic inclusions (NCIs), oligodendroglial,
coiled body–like cytoplasmic inclusions (GCIs), and dystro-
phic neurites (ﬁgure). GCIs and dystrophic neurites were
more frequent than NCIs. TDP43 pathology was most
prominent in the subthalamic nucleus, followed by the thal-
amus, putamen, and globus pallidus (other deep cerebral
nuclei were not available for the assessment), brainstem, and
spinal cord (table 1). NCIs with globular and skein-shaped
morphology were seen in both motor (anterior horn cells)
and sensory (dorsal root ganglion) neurons. In the neocortex,
subcortical hemispheric white matter, anterior hippocampus,
amygdala, and cingulate gyrus, TDP43 pathology was present
but very rare. In the cerebellum, there were GCIs in the white
matter and rare NCIs in the dentate nucleus but none in the
cerebellar cortex (table 1). TDP43-positive inclusions also
showed immunoreactivity for p62. There were no di-
agnostically speciﬁc p62 immunoreactive inclusions in the
cerebellum or hippocampal dentate gyrus to suggest
C9ORF72 pathology or neuronal intranuclear inclusions
characteristic of VCP or p62 mutations. Microglial activity,
highlighted with CD68 immunostaining, was most prominent
in the subthalamic nucleus with comparably mild activation
elsewhere, including the corticospinal tracts and anterior and
posterior nerve roots in the spinal cord. No β-amyloid,
α-synuclein, or signiﬁcant hyperphosphorylated tau pathology
was seen.
Discussion
In this report, we describe a case of FOSMN with personality
change and a postmortem examination characterized by
TDP43-positive inclusions in the cerebral cortex, brainstem,
and spinal cord motor neurons and DRGs. Our ﬁndings
corroborate the ﬁndings of 2 of 3 previous postmortem
examinations of patients with FOSMN in which TDP43
inclusions were identiﬁed in the brainstem.3,7,8 This report
provides further evidence that FOSMN may be considered
a forme fruste of bulbar-onset ALS, a notion further supported
by the behavioral change and TDP43 inclusions in the frontal
cortex. We were unable to measure β-amyloid42 and tau in the
CSF because this assay was not available 15 year ago at the
time of the patient’s illness. It should also be noted that al-
though the presence of TDP43 inclusions in the neocortex
was unequivocal, they were infrequent.
The clinical syndrome of FOSMNwas ﬁrst described in 2006,
several years after our patient’s death.2 Further histologic
analysis was prompted by reports of TDP43 inclusions in
postmortem tissue of patients with FOSMN.8 At the time of
our patient’s illness, mutations in C9ORF72, FUS, and
TARDBP had not yet been discovered to cause ALS.
This report also describes the identiﬁcation of TDP43
inclusions in the DRG of a patient with a sensory neuron-
opathy. This is an intriguing observation, and it is tempting to
speculate that a neurodegenerative pathology, characterized
by TDP43 inclusion in the DRG,may underlie a proportion of
patchy asymmetric sensory neuronopathies that follow
a progressive course and are resistant to immunosuppressive
therapy.9 In further support of the pathogenicity of the
TDP43 inclusions in the DRG is the recent report of a patient
with an asymmetric patchy and progressive sensory and mo-
tor neuronopathy in whom a p.Arg382Pro missense mutation
in TARDBP was discovered.10 This mutation is not present in
the Exac database and has previously been described in
Table 2 Neurophysiologic studies
Sensory nerves SAP, μV CV, m/s Motor nerves MCV DML, m/s CMAP, mV
Right median 13 54 Right median (APB) 3.1 12.4 54
Right sural 21 48.5 Right ulnar (ADM) 2.5 10.4 54
Right common peroneal 3.8 6.3 43
Right tibial (AH) 5.3 9.0 59
Abbreviations: ADM = abductor digiti minimii; AH = abductor hallucis; APB = abductor pollicis brevis; CMAP = compound muscle action potential; CV =
conduction velocity; DML = distal motor latency; MCV = motor conduction velocity; SAP = sensory action potential.
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patients with ALS.11 An additional distinctive feature seen in
this patient and reported in the literature8 is the presence of
widespread glial TDP43 pathology. TDP43-positive glial
inclusions are also observed in both ALS and frontotemporal
dementia–TDP, but to a much lesser extent, suggesting that
there might be diﬀerences in molecular pathogenesis between
FOSMN and ALS–frontotemporal dementia spectrum.
We describe TDP43 proteinopathy in a patient with FOSMN
and personality change. The presence of TDP43 proteinop-
athy in the brain, spinal cord, and DRG and the discovery of
a pathogenic TDP-43 mutation in a patient with an asym-
metric sensory and motor neuronopathy indicate that some
sensory neuronopathies have a degenerative pathogenesis.
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Figure TDP43 proteinopathy in FOSMN
(A) Pathologic thread-like deposits in a neuron within dorsal root ganglion. (B) Globular cytoplasmic inclusion in the lumbar anterior horn motor neuron. (C)
Large globular and skein-like (inset) cytoplasmic inclusions in pigmented neurons of the substantia nigra. (D–F) Various morphologies of neuronal cyto-
plasmic inclusions. (G– I) glial cytoplasmic inclusions, all of which show similar, coiled body–like morphology. (J–L) Appearances of dystrophic neurites, all of
which are short and curved with no evidence of long neurites. All sections are immunostained with nonphosphorylated TAR DNA-binding protein 43 (TDP43)
antibody, which detects normal nuclear TDP43 labeling and shows absent nuclear labeling in cells where there is TDP43 mislocalization from the nucleus to
cytoplasm or cell processes. Scale bar: 10 μm in panels A–L. FOSMN = facial-onset sensory and motor neuronopathy.
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